Continuous Glucose Monitoring

The CGM provides accurate readings over 10.5 days of continuous wear.

Significant differences in the use of insulin pump and/or CGM technology were noted based on demographic and socioeconomic factors

Dexcom expects the device to launch in the United States early next year.

New research adds more evidence of Black patients facing disparities in diabetes care.

Research shows that an increase in intermittent scanning helps improve glycemic control and reduce the fear of hypoglycemia.

Examining the benefits of using flash glucose monitoring in patients with type 1 diabetes.

The iLet Bionic Pancreas was associated with improved glycemic control and time in target glucose range compared to standard care in a cohort of people with type 1 diabetes aged 6-79 years of age.

Modeling indicates a significant increase in patients with type 1 diabetes over the next several years.

Research indicates that using an open-source automated insulin delivery systems can lead to greater glycemic control.

Software updates in closed-loop systems may lead to better time in range numbers for children with type 1 diabetes.

Improved glycemic control could reduce the risk of diabetes-related brain damage among teens and adolescents with type 1 diabetes.

Continuous glucose monitoring has many benefits and can improve disease management in for both diabetes types.